海量图书期刊资源,随时随地畅享阅读乐趣
PDB22 ASSESSING THE EFFICIENCY OF USING CONTINUOUS SUBCUTANEOUS INSULIN-INFUSION (CSII) VERSUS MULTIPLE DAILY INJECTIONS (MDI) IN SPANISH DIABETES MELLITUSTYPE-I (DM I) PATIENTS. COST—EFFECTIVENESS ANALYSISC Castell; AJ Palmer; JM Rodriguez; S Roze; D Serrano-Contreras; K Zakrzewska · 2005
PDB25 FIXED COMBINATION METFORMIN PLUS GLIBENCLAMIDE (GLUCOVANCE®) IS COST AND LIFE SAVING COMPARED TO METFORMIN PLUS ROSIGLITAZONE IN TYPE-2 DIABETES PATIENTS IN FRANCEN Cugnardey; S Roze; AJ Palmer; ME Minshall; WJ Valentine; C Renaudin · 2005
PCV82 VALIDATION OF A MODEL TO PREDICT LIFETIME CLINICAL AND ECONOMIC BENEFIT OF RAISING HDL-C IN STATINTREATED PATIENTS WITH PERSISTENTLY LOW HDL-CC Renaudin; W Berger; D Liens; WJ Valentine; AJ Palmer; S Roze · 2006
PCV17 PROJECTED IMPACT ON CORONARY HEART DISEASE OF ADDING PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) TO STATIN TREATMENT IN EUROPEAN PATIENTS WITH TYPE 2 DIABETESD Liens; AJ Palmer; WJ Valentine; C Renaudin; S Roze · 2006
PDB15 A COST-EFFECTIVENESS ANALYSIS OF SWITCHING TYPE-2 DIABETES PATIENTS FROM IMMEDIATE-RELEASE METFORMIN (GLUCOPHAGE®) TO A NEW EXTENDEDRELEASE FORMULATION OF METFORMIN (GLUCOPHAGE®XR)C Renaudin; S Roze; WJ Valentine; AJ Palmer · 2004
PDB8 CLINICAL BENEFITS OF PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) AND EZETIMIBE IN STATIN-TREATED TYPE-2 DIABETES PATIENTS FAILING TO REACH TARGET CHOLESTEROL LEVELSD Liens; S Roze; WJ Valentine; ME Minshall; AJ Palmer; C Renaudin · 2005
PDB18 COST-EFFECTIVENESS OF ADD-ON PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) THERAPY IN DIABETIC VERSUS NON-DIABETIC PATIENTS WITH DYSLIPIDEMIA: A UK PERSPECTIVEB Paschen; S Roze; AJ Palmer; WJ Valentine; D Liens; C Renaudin · 2005
PDB9 PROJECTED IMPACT ON CORONARY HEART DISEASE AT 5, 10 AND 35 YEARS OF ADDING PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) TO STATIN TREATMENT IN PATIENTS WITH TYPE-2 DIABETESC Renaudin; S Roze; AJ Palmer; WJ Valentine; ME Minshall; D Liens · 2005